Importantly, tumors with high median IFN-γ/IMS values, most notably SKCM33, colon adenocarcinoma (COAD), CESC34, BLCA35, lung squamous cell carcinoma (LUSC)36 and liver hepatocellular carcinoma (LIHC), have shown clinical sensitivity to ICI therapies (Fig. 3G). The gene discussed is IFNG; the disease is colon adenocarcinoma.